ARWR – arrowhead pharmaceuticals, inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

ARWR

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

12/1

08:09 am

arwr

Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.

Medium Report

Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.

Report

12/1

07:26 am

arwr

Rating for ARWR

Medium Report

Rating for ARWR

Report

11/26

09:52 am

arwr

Rating for ARWR

High Report

Rating for ARWR

Report

11/26

09:52 am

arwr

Rating for ARWR

High Report

Rating for ARWR

Report

11/20

07:42 am

arwr

Rating for ARWR

Medium Report

Rating for ARWR

Report

11/20

07:42 am

arwr

Rating for ARWR

Medium Report

Rating for ARWR

Report

11/20

07:42 am

arwr

Rating for ARWR

Medium Report

Rating for ARWR

Report

11/19

10:56 am

arwr

Rating for ARWR

Medium Report

Rating for ARWR

Report

11/19

10:56 am

arwr

Rating for ARWR

Medium Report

Rating for ARWR

Report

11/19

08:47 am

arwr

Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.

Medium Report

Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.

Report

11/19

08:20 am

arwr

Rating for ARWR

Medium Report

Rating for ARWR

Report

11/12

12:11 pm

arwr

Rating for ARWR

Low Report

Rating for ARWR

Report

11/12

12:11 pm

arwr

Rating for ARWR

Low Report

Rating for ARWR

Report

10/8

08:09 am

arwr

Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.

Low Report

Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.